Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…Abstract Number: 2329 • ACR Convergence 2025
Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
Background/Purpose: Psoriasis, a chronic inflammatory skin condition, is increasingly linked to systemic cardiovascular risks. Atrial fibrillation (AF), the most common cardiac arrhythmia, is associated with…Abstract Number: 1883 • ACR Convergence 2025
Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.
Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…Abstract Number: 1483 • ACR Convergence 2025
Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and accelerated atherosclerosis, leading to increased cardiovascular (CV) risk. While CV…Abstract Number: 1008 • ACR Convergence 2025
Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Background/Purpose: While two trials with colchicine have demonstrated its efficacy in reducing the risk of cardiovascular events, a more recent study showed no significant impact…Abstract Number: 0729 • ACR Convergence 2025
ANCA-associated vasculitis – does the type matter?
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a heterogeneous group of rare autoimmune disorders that cause inflammation of blood vessels with various manifestations. Our study…Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…Abstract Number: 2651 • ACR Convergence 2025
Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement
Background/Purpose: Systemic sclerosis (SSc) heart involvement (SHI) is a serious disease manifestation associated with high mortality. This study presents newly developed classification criteria to enable…Abstract Number: 2325 • ACR Convergence 2025
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…Abstract Number: 1851 • ACR Convergence 2025
Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by marked clinical variability, which complicates both diagnosis and treatment. Among its most severe…Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…Abstract Number: 0718 • ACR Convergence 2025
Incidence of Venous Thromboembolism in Patients with ANCA-Associated Vasculitides – a Nationwide Registry-Based Study from Sweden
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are rare yet severe autoimmune diseases. Previous studies have indicated that patients with AAV have an increased risk…Abstract Number: 0522 • ACR Convergence 2025
The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk of developing cardiovascular diseases, including arrhythmias. Given that traditional cardiovascular disease risk factors are prevalent…Abstract Number: 0120 • ACR Convergence 2025
The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Background/Purpose: Although antiphospholipid antibodies (aPL) are well-established risk factors for thrombosis, heritable thrombophilias (HT) are also associated with venous thromboembolism (VTE). The latter includes deficiencies…Abstract Number: 2642 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Inflammation is a driver of…
- 1
- 2
- 3
- …
- 38
- Next Page »